These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 33549543)

  • 1. Synthesis, pharmacological evaluation and Molecular modelling studies of pregnenolone derivatives as inhibitors of human dihydrofolate reductase.
    Bilal Tufail M; Aamir Javed M; Ikram M; Mahnashi MH; Alyami BA; Alqahtani YS; Sadiq A; Rashid U
    Steroids; 2021 Apr; 168():108801. PubMed ID: 33549543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitors of dihydrofolate reductase as antitumor agents: design, synthesis and biological evaluation of a series of novel nonclassical 6-substituted pyrido[3,2-d]pyrimidines with a three- to five-carbon bridge.
    Li H; Fang F; Liu Y; Xue L; Wang M; Guo Y; Wang X; Tian C; Liu J; Zhang Z
    Bioorg Med Chem; 2018 May; 26(9):2674-2685. PubMed ID: 29691154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2,4-diamino-5-deaza-6-substituted pyrido[2,3-d]pyrimidine antifolates as potent and selective nonclassical inhibitors of dihydrofolate reductases.
    Gangjee A; Vasudevan A; Queener SF; Kisliuk RL
    J Med Chem; 1996 Mar; 39(7):1438-46. PubMed ID: 8691474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and antiproliferative activity of a series of novel 6-substituted pyrido[3,2-d]pyrimidines as potential nonclassical lipophilic antifolates targeting dihydrofolate reductase.
    Wang M; Yang J; Yuan M; Xue L; Li H; Tian C; Wang X; Liu J; Zhang Z
    Eur J Med Chem; 2017 Mar; 128():88-97. PubMed ID: 28152430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, and X-ray crystal structure of a potent dual inhibitor of thymidylate synthase and dihydrofolate reductase as an antitumor agent.
    Gangjee A; Yu J; McGuire JJ; Cody V; Galitsky N; Kisliuk RL; Queener SF
    J Med Chem; 2000 Oct; 43(21):3837-51. PubMed ID: 11052789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human dihydrofolate reductase inhibition effect of 1-Phenylpyrazolo[3,4-d]pyrimidines: Synthesis, antitumor evaluation and molecular modeling study.
    Salem IM; Mostafa SM; Salama I; El-Sabbagh OI; A H Hegazy W; Ibrahim TS
    Bioorg Chem; 2022 Dec; 129():106207. PubMed ID: 36270170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of 5-alkyl modification on the biological activity of pyrrolo[2,3-d]pyrimidine containing classical and nonclassical antifolates as inhibitors of dihydrofolate reductase and as antitumor and/or antiopportunistic infection agents.
    Gangjee A; Jain HD; Queener SF; Kisliuk RL
    J Med Chem; 2008 Aug; 51(15):4589-600. PubMed ID: 18605720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and biological evaluation of novel 6-substituted pyrrolo [3,2-d] pyrimidine analogues as antifolate antitumor agents.
    Tian C; Wang M; Han Z; Fang F; Zhang Z; Wang X; Liu J
    Eur J Med Chem; 2017 Sep; 138():630-643. PubMed ID: 28711701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel 5-substituted, 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors with antiangiogenic and antitumor activity.
    Gangjee A; Zeng Y; Ihnat M; Warnke LA; Green DW; Kisliuk RL; Lin FT
    Bioorg Med Chem; 2005 Sep; 13(18):5475-91. PubMed ID: 16039863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and biological evaluation of 2,4-diamino-6-(arylaminomethyl)pyrido[2,3-d]pyrimidines as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase and as antiopportunistic infection and antitumor agents.
    Gangjee A; Adair OO; Queener SF
    J Med Chem; 2003 Nov; 46(23):5074-82. PubMed ID: 14584957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Applying the designed multiple ligands approach to inhibit dihydrofolate reductase and thioredoxin reductase for anti-proliferative activity.
    Ng HL; Chen S; Chew EH; Chui WK
    Eur J Med Chem; 2016 Jun; 115():63-74. PubMed ID: 26994844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 6-Substituted 2,4-diaminopyrido[3,2-d]pyrimidine analogues of piritrexim as inhibitors of dihydrofolate reductase from rat liver, Pneumocystis carinii, and Toxoplasma gondii and as antitumor agents.
    Gangjee A; Zhu Y; Queener SF
    J Med Chem; 1998 Nov; 41(23):4533-41. PubMed ID: 9804692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis of N-{4-[(2,4-diamino-5-methyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)thio]benzoyl}-L-glutamic acid and N-{4-[(2-amino-4-oxo-5-methyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)thio]benzoyl}-L-glutamic acid as dual inhibitors of dihydrofolate reductase and thymidylate synthase and as potential antitumor agents.
    Gangjee A; Lin X; Kisliuk RL; McGuire JJ
    J Med Chem; 2005 Nov; 48(23):7215-22. PubMed ID: 16279780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting dihydrofolate reductase: Design, synthesis and biological evaluation of novel 6-substituted pyrrolo[2,3-d]pyrimidines as nonclassical antifolates and as potential antitumor agents.
    Gao T; Zhang C; Shi X; Guo R; Zhang K; Gu J; Li L; Li S; Zheng Q; Cui M; Cui M; Gao X; Liu Y; Wang L
    Eur J Med Chem; 2019 Sep; 178():329-340. PubMed ID: 31200235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis, dihydrofolate reductase inhibition, anti-proliferative testing, and saturation transfer difference ¹H-NMR study of some new 2-substituted-4,6-diaminopyrimidine derivatives.
    Mohebbi S; Falcón-Pérez JM; González E; Millet O; Mato JM; Kobarfard F
    Chem Pharm Bull (Tokyo); 2012; 60(1):70-8. PubMed ID: 22223377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dihydrofolate reductase inhibition effect of 5-substituted pyrido[2,3-d]pyrimidines: Synthesis, antitumor activity and molecular modeling study.
    Abdelaziz OA; El Husseiny WM; Selim KB; Eisa HM
    Bioorg Chem; 2019 Sep; 90():103076. PubMed ID: 31260878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, docking studies and biological evaluation of novel dihydro-1,3,5-triazines as human DHFR inhibitors.
    Zhou X; Lin K; Ma X; Chui WK; Zhou W
    Eur J Med Chem; 2017 Jan; 125():1279-1288. PubMed ID: 27886545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and in vitro antitumor evaluation of new thieno[2,3-d]pyrimidine derivatives as EGFR and DHFR inhibitors.
    Fouad MM; Ghabbour HA; Shehata IA; El-Ashmawy MB
    Bioorg Chem; 2024 Jul; 148():107401. PubMed ID: 38749115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-based design and synthesis of lipophilic 2,4-diamino-6-substituted quinazolines and their evaluation as inhibitors of dihydrofolate reductases and potential antitumor agents.
    Gangjee A; Vidwans AP; Vasudevan A; Queener SF; Kisliuk RL; Cody V; Li R; Galitsky N; Luft JR; Pangborn W
    J Med Chem; 1998 Aug; 41(18):3426-34. PubMed ID: 9719595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase inhibitors and antitumor agents: synthesis and biological activities of 2,4-diamino-5-methyl-6-[(monosubstituted anilino)methyl] pyrido[2,3-d]pyrimidines.
    Gangjee A; Adair O; Queener SF
    J Med Chem; 1999 Jul; 42(13):2447-55. PubMed ID: 10395486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.